Sunshine Biopharma, Inc.

As of February 9, 2023, Sunshine Biopharma, Inc. is considered risky and overvalued due to significant losses and unfavorable valuation metrics, with a year-to-date return of -51.0% compared to the S&P 500's 12.22%.

As of February 9, 2023, Sunshine Biopharma, Inc. is classified as risky and overvalued, with poor financial metrics and a year-to-date stock performance of -52.33%, significantly underperforming the S&P 500's 2.44% return.

As of April 1, 2025, the trend is mildly bearish due to daily moving averages and Bollinger Bands signaling bearishness, despite some bullish indicators from MACD, KST, and monthly RSI.

Sunshine Biopharma, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $9 million and a net loss of $1 million as of March 2025. The company has a market cap of $6.70 million and key metrics indicating it is currently loss-making.

As of Jun 18, Sunshine Biopharma, Inc. has a market capitalization of 6.70 million, with net sales of 36.23 million and a net profit of -5.03 million over the last four quarters. The company reported shareholder's funds of 23.50 million and total assets of 30.56 million as of Dec 24.